JP2023519666A5 - - Google Patents

Info

Publication number
JP2023519666A5
JP2023519666A5 JP2022555137A JP2022555137A JP2023519666A5 JP 2023519666 A5 JP2023519666 A5 JP 2023519666A5 JP 2022555137 A JP2022555137 A JP 2022555137A JP 2022555137 A JP2022555137 A JP 2022555137A JP 2023519666 A5 JP2023519666 A5 JP 2023519666A5
Authority
JP
Japan
Prior art keywords
pyridine
carboxamide
trifluoromethyl
pyrazole
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022555137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519666A (ja
JP7492597B2 (ja
Filing date
Publication date
Priority claimed from GBGB2003668.7A external-priority patent/GB202003668D0/en
Application filed filed Critical
Publication of JP2023519666A publication Critical patent/JP2023519666A/ja
Publication of JP2023519666A5 publication Critical patent/JP2023519666A5/ja
Application granted granted Critical
Publication of JP7492597B2 publication Critical patent/JP7492597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022555137A 2020-03-13 2021-03-15 Gpr52モジュレーター化合物 Active JP7492597B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2003668.7 2020-03-13
GBGB2003668.7A GB202003668D0 (en) 2020-03-13 2020-03-13 GPR52 Modulator compounds
PCT/GB2021/050638 WO2021181122A1 (en) 2020-03-13 2021-03-15 Gpr52 modulator compounds

Publications (3)

Publication Number Publication Date
JP2023519666A JP2023519666A (ja) 2023-05-12
JP2023519666A5 true JP2023519666A5 (enExample) 2024-03-27
JP7492597B2 JP7492597B2 (ja) 2024-05-29

Family

ID=70453676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555137A Active JP7492597B2 (ja) 2020-03-13 2021-03-15 Gpr52モジュレーター化合物

Country Status (23)

Country Link
US (1) US12655120B2 (enExample)
EP (1) EP4117784B1 (enExample)
JP (1) JP7492597B2 (enExample)
KR (1) KR20220152296A (enExample)
CN (1) CN115515681B (enExample)
AU (1) AU2021235257B2 (enExample)
BR (1) BR112022018287A2 (enExample)
CA (1) CA3175429A1 (enExample)
DK (1) DK4117784T3 (enExample)
ES (1) ES2992600T3 (enExample)
FI (1) FI4117784T3 (enExample)
GB (1) GB202003668D0 (enExample)
HR (1) HRP20241375T1 (enExample)
HU (1) HUE068758T2 (enExample)
IL (1) IL296413B2 (enExample)
LT (1) LT4117784T (enExample)
MX (1) MX2022011333A (enExample)
PL (1) PL4117784T3 (enExample)
PT (1) PT4117784T (enExample)
RS (1) RS66063B1 (enExample)
SI (1) SI4117784T1 (enExample)
SM (1) SMT202400402T1 (enExample)
WO (1) WO2021181122A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
EP4330232A1 (en) * 2021-04-26 2024-03-06 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
GB202113186D0 (en) 2021-09-15 2021-10-27 Heptares Therapeutics Ltd GPR52 Modulator compounds
WO2024091541A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
WO2024091542A1 (en) * 2022-10-26 2024-05-02 Neurocrine Biosciences, Inc. Compounds and compositions as gpr52 modulators
AR130864A1 (es) * 2022-10-26 2025-01-29 Neurocrine Biosciences Inc Compuestos y composiciones como moduladores de gpr52
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327185A1 (en) 1998-04-08 1999-10-14 Abbott Laboratories Pyrazole inhibitors of cytokine production
US20010044445A1 (en) 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
NZ526624A (en) 2000-12-22 2005-07-29 Ortho Mcneil Pharm Inc Substituted triazole diamine derivatives as kinase inhibitors
US20040220170A1 (en) 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
WO2005037797A1 (en) * 2003-10-21 2005-04-28 Pharmacia Corporation Substituted pyrazole urea compounds for the treatment of inflammation
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
KR20100097077A (ko) 2009-02-25 2010-09-02 주식회사 중외제약 Hsp90에 대한 억제 효능을 갖는 피리디논 유도체
EP2518054A1 (en) 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
WO2017077280A1 (en) 2015-11-02 2017-05-11 Sonia Lain Tetrahydroindazoles and medical uses thereof
US11279703B2 (en) 2016-12-01 2022-03-22 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
CN111094278B (zh) 2017-09-13 2023-07-14 诺华股份有限公司 二苯基衍生物及其用途
JP7425724B2 (ja) 2017-10-17 2024-01-31 エピザイム,インコーポレイティド Ehmt2阻害剤としてのアミン置換複素環化合物及びその誘導体
AU2018353150B2 (en) 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
US20210213014A1 (en) 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
CN114650992A (zh) 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
GB202013558D0 (en) 2020-08-28 2020-10-14 Heptares Therapeutics Ltd GRP52 Modularor compounds

Similar Documents

Publication Publication Date Title
HRP20241375T1 (hr) Spojevi modulatora gpr52
AU2012313254B8 (en) Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors
JP6618525B2 (ja) ピラゾール類
JP2023539336A5 (enExample)
JP6254075B2 (ja) カリウムチャネル遮断剤としてのアミン誘導体
JP2012516890A5 (enExample)
JPH02104583A (ja) トリアゾール抗真菌剤
JP2017101071A (ja) Mekインヒビターおよびその使用方法
CN1950351B (zh) 适用作h3配体的3-或4-单取代酚及苯硫酚衍生物
JP2008534542A (ja) オキサゾール部分又はチアゾール部分を含む化合物、それらの製造方法及びそれらの使用
JP2018519253A5 (enExample)
CN1166173A (zh) 对σ和/或5HTIA受体具备活性的四氢吡啶-(或4-羟基哌啶)烷基吡咯
EP1585515A2 (en) Piperidine and pyrrolidine derivatives as antagonists of histamine h3 receptor
JP2011153144A (ja) 置換ピラゾール化合物
JP2018520170A5 (enExample)
CA2487688A1 (en) Piperidine derivative, process for producing the same, and use
JP2013505217A (ja) 置換n−フェニル−1−(4−ピリジニル)−1h−ピラゾル−3−アミン類
JP6186495B2 (ja) Cetp抑制活性を有する新規なオキサゾリジノン誘導体、その製造方法およびこれを含む薬学組成物
JP2020503302A5 (enExample)
WO2012020738A1 (ja) 複素環化合物およびその用途
WO2015012400A1 (ja) グリシントランスポーター阻害物質
CN1768043A (zh) 作为5-ht受体拮抗剂用于治疗精神病和神经病学障碍的1,3,4-取代的吡唑
JP2006522779A (ja) 4−置換キノリン誘導体、その調製方法、中間体及び医薬組成物
JP5452622B2 (ja) Nk3受容体アンタゴニストとしてのピロリジン誘導体
WO2007061741A2 (en) Modulators of the h3 receptor useful for the treatment of disorders related thereto